Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

University Of Cologne
Sponsor

University Of Cologne

Germany Albertus-Magnus-Platz 1, 50923 Cologne, Germany

About the sponsor

Clinical research includes classical Hodgkin lymphoma, relapsed/refractory chronic lymphocytic leukaemia, small lymphocytic lymphoma, Richter transformation, multiple myeloma, and primary central nervous system lymphoma. The portfolio also covers high-risk chronic lymphocytic leukaemia and treatment approaches for older or frail patients.

  • Classical Hodgkin lymphoma
  • Chronic lymphocytic leukaemia
  • Richter transformation
  • Multiple myeloma
  • Primary CNS lymphoma

Research activity spans immunotherapy, BTK inhibition, BCL2-targeted therapy, and anti-CD20-based combinations across aggressive and indolent haematological disease.

About Specializations

University Of Cologne runs clinical trials in conditions such as Chronic lymphocytic leukaemia, Hodgkin's disease, Corneal neovascularisation, Staphylococcal bacteraemia, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

25 clinical trials

Staphylococcal bacteraemia

Recruiting

Safety and Pharmacokinetics of MIB2 (StaphAcute) in Healthy Volunteers and Patients with Staphylococcus aureus Bacteremia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:University Of Cologne

Early switch to oral amoxicillin (drug combination) for adults with vertebral osteomyelitis: a randomised non‑inferiority trial

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:University Of Cologne

Chronic lymphocytic leukaemia

Recruiting

Evaluating the efficacy of pirtobrutinib and epcoritamab in patients with untreated Richter transformation of chronic lymphocytic leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:University Of Cologne

Herpes ophthalmic+1

Recruiting

Testing Aganirsen Eye Drops in Patients with Corneal Blood Vessel Growth from Herpes Eye Disease Before Corneal Transplant Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aganirsen
  • Sponsor:University Of Cologne

Hodgkin's disease

Recruiting

A Study of Pembrolizumab and Radiotherapy for Patients with Early-Stage Favorable Classic Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:University Of Cologne

Corneal neovascularisation

Recruiting

A Study of Aganirsen Eye Drops for Patients with Corneal Blood Vessel Growth in Aniridia-Associated Keratopathy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Aganirsen
  • Sponsor:University Of Cologne

Congenital cystic kidney disease

Recruiting

Testing dapagliflozin to slow kidney function decline in patients with autosomal dominant polycystic kidney disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Dapagliflozin
  • Sponsor:University Of Cologne

Hodgkin's disease

Recruiting

Study of pembrolizumab with drug combination for first-line treatment in patients with advanced-stage classic Hodgkin lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:University Of Cologne

Chronic lymphocytic leukaemia+1

Recruiting

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Chronic lymphocytic leukaemia

Recruiting

Study on Acalabrutinib, Obinutuzumab, and Venetoclax for Untreated High-Risk Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:University Of Cologne

Small cell lung cancer extensive stage

Recruiting

Study on Maintenance Therapy with Durvalumab and Olaparib for Patients with Extensive Disease Small-Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:University Of Cologne

Chronic lymphocytic leukaemia

Recruiting

Study on Zanubrutinib, Tislelizumab, and Sonrotoclax for Patients with Richter Transformation (a type of lymphoma)

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Tislelizumab
  • Sponsor:University Of Cologne

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.